EU Slow on TB Drug Resistance

The European Union is facing criticism for its perceived lack of urgency in addressing the growing threat of drug-resistant tuberculosis (TB). Pharmaceutical companies are reporting significant difficulties in developing and producing new medications to combat these evolving strains of the disease. This situation raises concerns about public health across Europe and globally, demanding a more proactive response from the EU.

Summarized from the sources above. Read the originals for the full story.